Top Story

Ocular Therapeutix announces Q2 financial results

September 2, 2014

Ocular Therapeutix has announced its second-quarter financial results, which included a net loss attributable to common stockholders of approximately $6.4 million, or $2.10 per share, compared with $3.1 million, or $1.19 per share, during the same time last year.

Q2 financial results also included $3.4 million in non-cash charges for stock-based compensation and licensing and consultant fees paid in common stock, compared with $0.2 million for similar charges in 2013, according to a company press release.

In the Journals

Fenofibrate slows diabetic retinopathy progression in at-risk patients

September 2, 2014
Intensive treatment of glycemia and dyslipidemia slowed the progression of diabetic retinopathy in diabetic patients with cardiovascular disease or associated risk…

Allergan responds to Valeant, Pershing Square counterclaims

September 2, 2014
Allergan has filed an answer in the U.S. District Court for the Central District of California in response to Valeant Pharmaceuticals and Pershing Square Capital…
Breaking News

Ozurdex approved in EU for treatment of DME

September 2, 2014
The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press…
More News Headlines »
Case Report

Uveal Melanoma Gene Expression Profile Test Result Provided for Uveal Metastasis

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, August 26, 2014
The DecisionDx-UM gene expression profiling test is an accurate, popular, and technically simple method for obtaining…
More »
CME

OCT in the Management of Macular Degeneration

This activity is supported by an educational grant from Carl Zeiss Meditec.

5/13/2014
Advances in retinal pharmacology have significantly improved outcomes for patients with a range of chronic retinal…
More »
Meeting News Coverage Video
figure

Speaker discusses HOME study

August 13, 2014
At the American Society of Retina Specialists meeting in San Diego, David S. Boyer, MD, discusses results from the HOME…
More »